Charles Bennett to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Charles Bennett has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.897
-
Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest. 1997; 15(3):227-36.
Score: 0.131
-
Economic analysis during phase III clinical trials: who, what, when, where, and why? Oncology (Williston Park). 1995 Nov; 9(11 Suppl):169-75.
Score: 0.120
-
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol. 1995 Sep; 13(9):2457-63.
Score: 0.119
-
Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Stem Cells. 1995 Jul; 13(4):414-20.
Score: 0.118
-
Economic analysis in phase III clinical cancer trials. Cancer Invest. 1994; 12(3):336-42.
Score: 0.106
-
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27(26):4398-405.
Score: 0.078
-
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med. 2008 Mar 24; 168(6):632-42.
Score: 0.071
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27; 299(8):914-24.
Score: 0.071
-
Clinical trials: are they a good buy? J Clin Oncol. 2001 Dec 01; 19(23):4330-9.
Score: 0.046
-
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 1):40-5.
Score: 0.038